INDICATION & USAGE
DALVANCE® (dalbavancin) for injection is indicated for the treatment of adult patients with acute bacterial
skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive
microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains),
Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus
group (including S. anginosus, S. intermedius, S. constellatus) and
Enterococcus faecalis (vancomycin-susceptible strains).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial
agents, DALVANCE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
IMPORTANT SAFETY INFORMATION
DALVANCE is contraindicated in patients with known hypersensitivity to dalbavancin.
Warnings and Precautions
Serious hypersensitivity (anaphylactic) and skin reactions have been reported with glycopeptide antibacterial agents,
including DALVANCE. Exercise caution in patients with known hypersensitivity to glycopeptides due to the possibility
of cross-sensitivity. If an allergic reaction occurs, treatment with DALVANCE should be discontinued.
Rapid intravenous infusion of DALVANCE can cause reactions, including flushing of the upper body,
urticaria, pruritus, and rash.
ALT elevations with DALVANCE treatment were reported in clinical trials.
Clostridium difficile-associated Diarrhea
Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial
agents, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.
Development of Drug-resistant Bacteria
Prescribing DALVANCE in the absence of a proven or strongly suspected bacterial infection is unlikely to provide
benefit to the patient and increases the risk of the development of drug-resistant bacteria.
The most common adverse reactions in patients treated with DALVANCE were nausea (4.7%), headache (3.8%), and diarrhea (3.4%).
Use in Specific Populations
There have been no adequate and well-controlled studies with DALVANCE in pregnant or nursing women.
DALVANCE should only be used if the potential benefit justifies the potential risk in these populations.
In patients with renal impairment whose known creatinine clearance is less than 30 mL/min and who
are not receiving regularly scheduled hemodialysis, the recommended regimen of DALVANCE is 1125 mg,
administered as a single dose, or 750 mg followed one week later by 375 mg. No dosage adjustment is
recommended for patients receiving regularly scheduled hemodialysis, and DALVANCE can be administered
without regard to the timing of hemodialysis.
Caution should be exercised when prescribing DALVANCE to patients with moderate or severe hepatic
impairment (Child-Pugh Class B or C) as no data are available to determine the appropriate dosing
in these patients.
Please see Full